Naturally occurring antibodies as therapeutics for neurologic disease can human monoclonal IgMs replace the limited resource IVIG?

Advances in Experimental Medicine and Biology

Volumn 750, Issue , 2012, Pages 44-55

  Warrington, Arthur E ^a   Van Keulen, Virginia ^a   Pease, Larry R ^a   Rodriguez, Moses ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; NATURAL ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; CALCIUM; IMMUNOGLOBULIN; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; ANTIGEN BINDING; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CALCIUM SIGNALING; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CROSS LINKING; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NERVE CELL; NEUROLOGIC DISEASE; NONHUMAN; OLIGODENDROGLIA; OPTIC NEURITIS; PRIORITY JOURNAL; REMYELINIZATION; IMMUNOLOGY; METABOLISM; PASSIVE IMMUNIZATION;

ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; B-LYMPHOCYTES; CALCIUM; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS;

EID: 84866782855     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3461-0_4     Document Type: Article

References (48)

1. Lacroix-Desmazes S, Kaveri SV, Mouthon L et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 1998; 216:117-37. PMID:9760219 doi:10.1016/S0022-1759(98)00074-X (Pubitemid 28440383)
2. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995; 7:812-8. PMID:8679125 doi:10.1016/0952-7915(95)80053-0 (Pubitemid 26038522)
3. Gold R, Stangel M, Dalakas MC. Drug Insight: The use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3:36-44. PMID:17205073 doi:10.1038/ncpneuro0376 (Pubitemid 46056032)
4. Noseworthy JH, Lucchinetti C, Rodriguez M et al. Multiple sclerosis. N Engl J Med 2000; 343:938-52. PMID:11006371 doi:10.1056/NEJM200009283431307
5. Fazekas F, Deisenhammer F, Strasser-Fuchs S et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349:589-93. PMID:9057729 doi:10.1016/S0140-6736(96)09377-4 (Pubitemid 27101884)
6. Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50:1273-81. PMID:9595974 (Pubitemid 28240339)
7. Haas J, Maas-Enriquez M, Hartung HP. Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis-results of a retrospective multicenter observational study over five years. Mult Scler 11:562-7. PMID:16193894 doi:10.1191/1352458505ms1224oa
8. Fazekas F, Lublin FD, Li D et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial. Neurology 2008; 71:265-71. PMID:18645164 doi:10.1212/01.wnl.0000318281.98220.6f
9. Hommes OR, Sorensen PS, Fazekas F et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364:1149-56. PMID:15451222 doi:10.1016/ S0140-6736(04)17101-8
10. McDonald WI, Barnes D. The ocular manifestations of multiple sclerosis. 1. Abnormalities of the afferent visual system. J Neurol Neurosurg Psychiatry 1992; 55:747-52. PMID:1402963 doi:10.1136/jnnp.55.9.747
11. Noseworthy JH, O'Brien PC, Petterson TM et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56:1514-22. PMID:11402108 (Pubitemid 32532263)
12. Roed HG, Langkilde A, Sellebjerg F et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64:804-10. PMID:15753413 doi:10.1212/01. WNL.0000152873.82631.B3 (Pubitemid 40316316)
13. Noseworthy JH, O'Brien PC, Weinshenker BG et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000; 55:1135-43. PMID:11071491
14. Tselis A, Perumal J, Caon C et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008; 15:1163-7. PMID:18727675 doi:10.1111/j.1468-1331.2008.02258.x
15. Rodriguez M, Oleszak E, Leibowitz J. Theiler's murine encephalomyelitis: A model of demyelination and persistence of virus. Crit Rev Immunol 1987; 7:325-65. PMID:2827957
16. McGavern DB, Murray PD, Rivera-Quinones C et al. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000; 123:519-31. PMID:10686175 doi:10.1093/ brain/123.3.519 (Pubitemid 30099537)
17. McGavern DB, Murray PD, Rodriguez M. Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. J Neurosci Res 1999; 58:492-504. PMID:10533042 doi:10.1002/(SICI)1097-4547(19991115)58:4<492::AID-JNR3>3.0.CO;2-P (Pubitemid 29530433)
18. McGavern DB, Zoecklein L, Drescher KM et al. Quantitative assessment of neurologic deficits in a chronic progressive murine model of CNS demyelination. Exp Neurol 1999; 158:171-81. PMID:10448429 doi:10.1006/exnr.1999.7082 (Pubitemid 29344329)
19. Rodriguez M, Lennon VA, Benveniste EN et al. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol 1987; 46:84-95. PMID:2432195 doi:10.1097/00005072-198701000-00008 (Pubitemid 17232257)
20. Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990; 27:12-7. PMID:2301922 doi:10.1002/ana.410270104 (Pubitemid 20031353)
21. Huang DW, McKerracher L, Braun PE et al. A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. Neuron 1999; 24:639-47. PMID:10595515 doi:10.1016/ S0896-6273(00)81118-6
22. Ellezam B, Bertrand J, Dergham P et al. Vaccination stimulates retinal ganglion cell regeneration in the adult optic nerve. Neurobiol Dis 2003; 12:1-10. PMID:12609484 doi:10.1016/S0969-9961(02)00013-X (Pubitemid 36262034)
23. Miller DJ, Sanborn KS, Katzmann JA et al. Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis. J Neurosci 1994; 14:6230-8. PMID:7931575 (Pubitemid 24307813)
24. Asakura K, Miller DJ, Murray K et al. Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes. J Neurosci Res 1996; 43:273-81. PMID:8714516 doi:10.1002/(SICI)1097-4547(19960201)43:3<273::AID-JNR2>3.0.CO;2-G (Pubitemid 26057424)
25. Warrington AE, Pfeiffer SE. Proliferation and differentiation of O4+ oligodendrocytes in postnatal rat cerebellum: Analysis in unfixed tissue slices using anti-glycolipid antibodies. J Neurosci Res 1992; 33:338-53. PMID:1453495 doi:10.1002/jnr.490330218
26. Asakura K, Miller DJ, Pease LR et al. Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. J Neurosci 1998; 18:7700-8. PMID:9742140 (Pubitemid 28441011)
27. Asakura K, Miller DJ, Pogulis RJ et al. Oligodendrocyte-reactive O1, O4, and HNK-1 monoclonal antibodies are encoded by germline immunoglobulin genes. Brain Res Mol Brain Res 1995; 34:283-93. PMID:8750831 doi:10.1016/0169-328X(95) 00190-4 (Pubitemid 26007084)
28. Avrameas S, Ternynck T, Tsonis IA et al. Naturally occurring B-cell autoreactivity: A critical overview. J Autoimmun 2007; 29:213-8. PMID:17888629 doi:10.1016/j.jaut.2007.07.010 (Pubitemid 47633147)
29. Warrington AE, Asakura K, Bieber AJ et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA 2000; 97:6820-5. PMID:10841576 doi:10.1073/pnas.97.12.6820 (Pubitemid 30412798)
30. Brown NA, Miller G. Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus. J Immunol 1982; 128:24-9. PMID:6274955 (Pubitemid 12207414)
31. Mitsunaga Y, Ciric B, Van Keulen V et al. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J 2002; 16:1325-7. PMID:12154009
32. Bieber AJ, Warrington A, Asakura K et al. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 2002; 37:241-9. PMID:11857682 doi:10.1002/glia.10033
33. Warrington AE, Bieber AJ, Ciric B et al. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 2007; 85:967-76. PMID:17304578 doi:10.1002/jnr.21217 (Pubitemid 46580338)
34. Pirko I, Ciric B, Gamez J et al. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J 2004; 18:1577-9. PMID:15319372 (Pubitemid 39561638)
35. Hunter SF, Miller DJ, Rodriguez M. Monoclonal remyelination-promoting natural autoantibody SCH.03: Pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis. J Neurol Sci 1997; 150:103-13. PMID:9268236 doi:10.1016/S0022-510X(97)00080-4 (Pubitemid 27317687)
36. Banks WA, Farr SA, Morley JE et al. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairment. Exp Neurol 2007; 206:248-56. PMID:17582399 doi:10.1016/j.expneurol.2007.05.005 (Pubitemid 47094769)
37. Paz Soldán MM, Warrington AE, Bieber AJ et al. Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci 2003; 22:14-24. PMID:12595235 doi:10.1016/S1044-7431(02) 00018-0 (Pubitemid 36269112)
38. Watzlawik J, Holicky E, Edberg DD et al. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia 2010; 58:1782-93. PMID:20645409 doi:10.1002/glia.21048
39. Ciric B, Howe CL, Paz Soldan M et al. Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol 2003; 13:608-16. PMID:14655764 doi:10.1111/j.1750-3639.2003. tb00489.x (Pubitemid 37420703)
40. Schroeder HW Jr., Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010; 125(Suppl 2):S41-52. PMID:20176268 doi:10.1016/j.jaci.2009.09.046
41. Howe CL, Bieber AJ, Warrington AE et al. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody. Neurobiol Dis 2004; 15:120-31. PMID:14751777 doi:10.1016/j.nbd.2003.09.002 (Pubitemid 38134387)
42. Dodel R, Hampel H, Depboylu C et al. Human antibodies against amyloid beta peptide: A potential treatment for Alzheimer's disease. Ann Neurol 2002; 52:253-6. PMID:12210803 doi:10.1002/ana.10253 (Pubitemid 34810613)
43. Dodel RC, Du Y, Depboylu C et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004; 75:1472-4. PMID:15377700 doi:10.1136/jnnp. 2003.033399 (Pubitemid 39279821)
44. Geylis V, Kourilov V, Meiner Z et al. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005; 26:597-606. PMID:15708434 doi:10.1016/j.neurobiolaging.2004.06.008 (Pubitemid 40228751)
45. Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev 2008; 7:415-20. PMID:18558354 doi:10.1016/j.autrev.2008. 03.007
46. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7. PMID:10408445 doi:10.1038/22124 (Pubitemid 29327547)
47. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-9. PMID:10932230 doi:10.1038/78682
48. Lindhagen-Persson M, Brannstrom K, Vestling M et al. Amyloid-beta oligomer specificity mediated by the IgM isotype-implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLoS ONE 2010; 5:e13928. PMID:21085663 doi:10.1371/journal.pone.0013928